Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7)
Year: 2014
Type: conference-abstract
Abstract: reported fewer AEs compared to BRAFi-naive pts. Most common AEs in BRAFi-naive pts (n=63) were non-acneiform rash (89%), diarrhea (81%), photosensitivity/sunburn (70%), fatigue (67%) and liver test abnormality (59%). Most frequent grade ≥3 AEs in BRAFi-naive pts were liver test abnormality (19%), non-acneiform rash (13%), arthral
Institutions: Vanderbilt University, Vanderbilt-Ingram Cancer Center, Peter MacCallum Cancer Centre, University of Colorado Cancer Center, New York University, Angeles Clinic and Research Institute, University of Chicago, Genentech, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,890
OpenAlex ID: W2009460720